Finch Therapeutics Group, Inc.
FNCHOTCHealthcare● Active
$7.45
+$0.00(+0.00%)
Market Cap$11962934
P/E Ratio—
52W High$16.1
52W Low$2
Finch Therapeutics Group, Inc. (FNCH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FNCH · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 13, 2024EPS Actual
-$3.01
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 13, 2024
After Market Close
✓ 1-Quarter EPS Beat Streak
FNCH reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2026 | Mar 27, 2026 | -$30.00 | — | — | — | $0.00B | — |
| — Q3 FY2024 | Aug 13, 2024 | — | -$3.01 | — | — | — | — |
| — Q2 FY2024 | May 10, 2024 | — | -$2.41 | — | — | — | — |
| — Q1 FY2024 | Mar 25, 2024 | — | -$1.89 | — | $0.00B | — | — |
| — Q4 FY2023 | Nov 8, 2023 | — | -$1.51 | — | — | — | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | -$4.51 | -$4.33 | +4.0% | — | — | — |
| ▼ Q2 FY2023 | May 10, 2023 | -$2.70 | -$15.62 | -478.5% | $0.00B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | -$16.48 | — | $0.00B | — | — |
Q1 FY2026
Mar 27, 2026
EPS Actual
—
EPS Est.
-$30.00
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 13, 2024
EPS Actual
-$3.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 10, 2024
EPS Actual
-$2.41
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 25, 2024
EPS Actual
-$1.89
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Nov 8, 2023
EPS Actual
-$1.51
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$4.33
EPS Est.
-$4.51
EPS Surpr.
+4.0%
Revenue
—
Q2 FY2023
May 10, 2023Miss
EPS Actual
-$15.62
EPS Est.
-$2.70
EPS Surpr.
-478.5%
Revenue
$0.00B
Q4 FY2022
Dec 31, 2022
EPS Actual
-$16.48
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $-5.67 | $-5.67 | $-5.67 | 1 |
| Q2 FY2028 | $-5.67 | $-5.67 | $-5.67 | 1 |
| Q1 FY2028 | $-4.50 | $-4.50 | $-4.50 | 1 |
| Q4 FY2027 | $-2.70 | $-2.70 | $-2.70 | 1 |
| Q3 FY2027 | $-9.90 | $-9.90 | $-9.90 | 1 |
| Q2 FY2027 | $-12.60 | $-12.60 | $-12.60 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2024 | Aug 13, 2024 | — | $9.50 | $10.09 | +6.21% |
| — Q2 FY2024 | May 10, 2024 | — | $2.03 | $2.01 | -0.99% |
| — Q1 FY2024 | Mar 25, 2024 | — | $2.57 | $2.70 | +5.06% |
| — Q4 FY2023 | Nov 8, 2023 | — | $3.80 | $3.79 | -0.26% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +4.0% | $7.00 | $6.60 | -5.71% |
| ▼ Q2 FY2023 | May 10, 2023 | -478.5% | $12.60 | $11.85 | -5.95% |
| — Q4 FY2022 | Dec 31, 2022 | — | $14.40 | $13.62 | -5.42% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -12.5% | $30.75 | $31.50 | +2.44% |
Q3 FY2024+6.21%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$9.50
Price After
$10.09
Q2 FY2024-0.99%
Report Date
May 10, 2024
EPS Beat/Miss
—
Price Before
$2.03
Price After
$2.01
Q1 FY2024+5.06%
Report Date
Mar 25, 2024
EPS Beat/Miss
—
Price Before
$2.57
Price After
$2.70
Q4 FY2023-0.26%
Report Date
Nov 8, 2023
EPS Beat/Miss
—
Price Before
$3.80
Price After
$3.79
Q3 FY2023-5.71%
Report Date
Aug 10, 2023
EPS Beat/Miss
+4.0%
Price Before
$7.00
Price After
$6.60
Q2 FY2023-5.95%
Report Date
May 10, 2023
EPS Beat/Miss
-478.5%
Price Before
$12.60
Price After
$11.85
Q4 FY2022-5.42%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$14.40
Price After
$13.62
Q4 FY2022+2.44%
Report Date
Nov 10, 2022
EPS Beat/Miss
-12.5%
Price Before
$30.75
Price After
$31.50
Avg Beat Reaction-5.71%
Avg Miss Reaction-1.76%
Beat Rate1 / 8 quarters
Largest Move+6.21% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FNCH ends December
Finch Therapeutics Group, Inc. (FNCH) most recently reported earnings on August 13, 2024 for Q3 FY2024, posting EPS of $-3.01 (in line with the analyst consensus of —). The next FNCH earnings date is expected around September 1, 2026.
Each quarter, investors track FNCH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FNCH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FNCH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FNCH earnings · 4 questionsFinch Therapeutics Group, Inc.'s next earnings report is expected around September 1, 2026. FNCH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FNCH historically reports after market close (AMC).
FNCH earnings datewhen is FNCH earningsFNCH next earnings datewhen does FNCH report earningsFNCH earnings calendar
▸ Source: FMP · Finch Therapeutics Group, Inc. SEC filings · US GAAP · Finch Therapeutics Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026